Posters –
Cardiometabolic diseases
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Nanotechnology-based development of novel "artificial islets" inducer in vitro
Jean-Paul Lellouche (JPL)
Bar-Ilan University & Institute of Nanotechnology & Advanced Materials
Technology
This technology uses an innovative « clusterization » phenomenon via functional
magnetic (iron oxide) nanoparticles functionalization by in-silico designed anti-diabetic
neuroligin-derived peptides. Such laboratory-level studies afforded quite significant
results concerning anti-diabetic activity (beta-cell function enhancement) with potential
promotion of reinforced transplanted beta-cell survival in vivo together with strong MRI
T2* tracking capability
Customers / Target market
• All industry involved in anti-diabetic human therapy as well as interested by novel
peptide-iron oxide composite nanoparticle-based therapeutical approaches dealing with
peptide delivery
• Targeted market as potentially relevant to last laboratory results is dealing with antidiabetic human treatments
Industry and competitors
All big pharma actors in anti-diabetes therapy fields.
Financing need / Commercial
opportunity
Need to develop relevant bio-nanotechnology cooperative works and technology
validation concerning different human diseases beyond the one cited above. First stepcooperative activity funding might be made on the basis of IP sharing including scientific
cooperative action/work. For example, bi-sided cooperative projects might be set-up on
the basis on 1/1.5 year activity and for potential budgets in a 80-120 k$ frame.
IP – Patent situation
• Patent registration (on-going process) involving both Bar-Ilan & Californy universities –
Process that should be soon closed hopefully
• In case of future cooperative works, there should not be any issue to promote new IP
patent applications that might be shared between cooperating actors
Future steps / Milestones
• Further validation of the corresponding technology using independent biology-related
actors/cooperative industries and/or academic groups – 0-6 months
• Set-up of novel relating industry-academy (BIU) cooperations in such human disease
fields for widest screening of such peptide/peptide derivatives and analogs delivery
systems potential - 1-3 years duration period
• Such steps must be closed within this present year for strongest effectiveness at least at
the level of cooperative agreements – 0-6 Mths period
Further reading
N/A
Contact person
Lellouche Jean-Paul , Prof. - Bar-Ilan University, Dpt of Chemistry, Building n° 211
(Gradel), Max & Anna Web, Ramat-Gan, 5290002 Israel - E-mail : lellouj@biu.ac.il